You can buy or sell Atreca and other stocks, options, and ETFs commission-free!
Atreca, Inc. Class A Common Stock, also called Atreca, is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in South San Francisco, CA. The listed name for BCEL is Atreca, Inc. Class A Common Stock.
John A. Orwin
South San Francisco, California
52 Week High
52 Week Low
— per share
Expected Mar 11, Pre-Market